Investing in excellenceStart Date 18/02/2014
IMI Investing in Excellence - SME networking event
On 18 February 2014, at Le Méridien hotel, Brussels, IMI and the International Venture Club (IVC) welcomed over 120 leading life science investors, health entrepreneurs, corporate investors and small and medium-sized enterprises (SMEs) involved in IMI to its Investing in excellence networking event.
The meeting focused on giving SMEs plenty of opportunities to meet specialist venture capitalists and industry investors, both formally and informally, and to hear from specialists in the finance and investment sectors on their views for new opportunities for entrepreneurship within life sciences. Carlo Incerti presented the IMI model of public-private partnership which is addressing the challenges faced by the drug research and development community, followed by a presentation from Jean-David Malo about funding opportunities for SMEs under the new Horizon 2020 programme. Ruth McKernan presented a case study on the development of the commercial model for stem cells to illustrate how SMEs can offer new business models for big pharma for the future.
|L to R:Carlo Incerti-Ruth McKernan-Stephane Dhulluin-Brian Hashemi-Jean-David Malo-Jasper Bos-Johan Verbeek-Charlotte Howard|
Charlotte Howard, Healthcare Correspondent at The Economist moderated an interesting debate with 7 expert panellists in pharma and venture capital. The debate was followed by a series of dynamic 45-second 'elevator pitches' from more than 26 SMEs and venture capitalists attending the event, and was moderated by William Stevens, Founding & Managing Director, of Europe Unlimited
The morning session was followed by a networking. lunch. Networking between SMEs and VCs continued in a series of private 'speed meetings' for the afternoon session, and informal networking continued outside of the meeting until the close at 16.30.
Download the agenda
- IMI:towards a new ecosystem in healthcare
Carlo Incerti, IMI Governing Board & Head of Global Medical Affairs, Genzyme
- Horizon 2020: focusing on funding for SMEs
Jean David Malo, Head of Unit, DG Research and Innovation (Directorate C3 for Financial Engineering)
- The role of SMEs in therapeutic innovation: EFPIA's vision
Ruth McKernan, EFPIA RDG member & Chief Scientific Officer, Neusentis Unit, Pfizer